Value_Investor
1週前
It is Super Hard to understand why this Hidden Gem has $5.4286 per share Huge POSITIVE Book Value but it is trading at such Ridiculous-Low or Huge Discount price levels $1.3x ~ $1.4x?
If I had $3,045,828.80 cash at hand then I'm willing to Buy-Out the Entire OS at current Huge Discount Dirt Cheap price $1.36 because 2,239,580 x $1.36 = $3,045,828.80!
georgie18
2週前
VINC...$1.69...🥳
georgie18
Member Level
Re: None
Saturday, February 01, 2025 3:12:37 PM
Post#
31347
of 31358
VINC...$1.58...🥳...https://schrts.co/xpMPMrhfh ...Bullish Deliberation Block Reversal Pattern...on this Oversold Chart... 2million Range Float Post Split...
georgie18
Member Level
Re: georgie18 post# 31
Wednesday, January 29, 2025 8:28:50 AM
Post#
51
of 54
VINC...$2.11 ...Post Split...🥳... Vincerx-Pharma-Inc-and-Oqory-Inc-Highlight-Promising-Data-for-Oqory-s-TROP2-Antibody-Drug-Conjugate-OQY-3258.html" rel="nofollow noopener noreferrer ugc" target="_blank">https://www.globenewswire.com/news-release/2025/01/29/3017128/0/en/Vincerx-Pharma-Inc-and-Oqory-Inc-Highlight-Promising-Data-for-Oqory-s-TROP2-Antibody-Drug-Conjugate-OQY-3258.html
georgie18
Member Level
Re: georgie18 post# 387642
Friday, December 27, 2024 4:35:45 PM
Post#
387643
of 389318
VINC...40s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 29
Friday, December 27, 2024 4:19:41 PM
Post#
30
of 30
VINC....1946...🥳...Alerted at 2954...PALO ALTO, Calif., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it has entered into a binding term sheet for a proposed merger with Oqory, Inc., a privately-held, clinical-stage company developing ADCs for the treatment of multiple oncology indications.
Upon completion of the proposed merger, Oqory, Inc. will merge with Vincerx Pharma, Inc. Post-closing, Oqory equity holders are expected to own approximately 95% of the combined entity, while Vincerx equity holders will hold about 5%. The transaction includes a minimum fully diluted equity value of $13.66 million for existing Vincerx stockholders at closing and, as a condition to the closing of the merger, completion of a concurrent offering of Vincerx equity securities of at least $20 million. Additionally, Oqory-designated investors will provide interim financing to Vincerx of $1.5 million in two tranches, approximately $1,000,000 of which was funded today through the issuance of common stock and pre-funded warrants along with accompanying common stock warrants and approximately $500,000 of which will be funded on or prior to January 31, 2025. The merger is subject to customary closing conditions, including due diligence, regulatory approvals, negotiation of a definitive merger agreement, stockholder approval from both parties, completion of the minimum $20 million financing, and the continued listing of Vincerx's common stock on Nasdaq.
georgie18
Member Level
Re: georgie18 post# 386297
Monday, December 09, 2024 4:01:30 PM
Post#
386750
of 387642
VINC...2194...added here today...🥳
georgie18
Member Level
Re: None
Monday, December 02, 2024 9:42:03 AM
Post#
28
of 28
VINC...2954...🥳...Trying to Reverse here to the Upside...
georgie18
2週前
VINC...$1.58...🥳...https://schrts.co/xpMPMrhfh ...Bullish Deliberation Block Reversal Pattern...on this Oversold Chart... 2million Range Float Post Split...
georgie18
Member Level
Re: georgie18 post# 31
Wednesday, January 29, 2025 8:28:50 AM
Post#
51
of 54
VINC...$2.11 ...Post Split...🥳... https://www.globenewswire.com/news-release/2025/01/29/3017128/0/en/Vincerx-Pharma-Inc-and-Oqory-Inc-Highlight-Promising-Data-for-Oqory-s-TROP2-Antibody-Drug-Conjugate-OQY-3258.html
georgie18
Member Level
Re: georgie18 post# 387642
Friday, December 27, 2024 4:35:45 PM
Post#
387643
of 389318
VINC...40s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 29
Friday, December 27, 2024 4:19:41 PM
Post#
30
of 30
VINC....1946...🥳...Alerted at 2954...PALO ALTO, Calif., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it has entered into a binding term sheet for a proposed merger with Oqory, Inc., a privately-held, clinical-stage company developing ADCs for the treatment of multiple oncology indications.
Upon completion of the proposed merger, Oqory, Inc. will merge with Vincerx Pharma, Inc. Post-closing, Oqory equity holders are expected to own approximately 95% of the combined entity, while Vincerx equity holders will hold about 5%. The transaction includes a minimum fully diluted equity value of $13.66 million for existing Vincerx stockholders at closing and, as a condition to the closing of the merger, completion of a concurrent offering of Vincerx equity securities of at least $20 million. Additionally, Oqory-designated investors will provide interim financing to Vincerx of $1.5 million in two tranches, approximately $1,000,000 of which was funded today through the issuance of common stock and pre-funded warrants along with accompanying common stock warrants and approximately $500,000 of which will be funded on or prior to January 31, 2025. The merger is subject to customary closing conditions, including due diligence, regulatory approvals, negotiation of a definitive merger agreement, stockholder approval from both parties, completion of the minimum $20 million financing, and the continued listing of Vincerx's common stock on Nasdaq.
georgie18
Member Level
Re: georgie18 post# 386297
Monday, December 09, 2024 4:01:30 PM
Post#
386750
of 387642
VINC...2194...added here today...🥳
georgie18
Member Level
Re: None
Monday, December 02, 2024 9:42:03 AM
Post#
28
of 28
VINC...2954...🥳...Trying to Reverse here to the Upside...
georgie18
3週前
VINC...$2.11 ...Post Split...🥳... https://www.globenewswire.com/news-release/2025/01/29/3017128/0/en/Vincerx-Pharma-Inc-and-Oqory-Inc-Highlight-Promising-Data-for-Oqory-s-TROP2-Antibody-Drug-Conjugate-OQY-3258.html
georgie18
Member Level
Re: georgie18 post# 387642
Friday, December 27, 2024 4:35:45 PM
Post#
387643
of 389318
VINC...40s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 29
Friday, December 27, 2024 4:19:41 PM
Post#
30
of 30
VINC....1946...🥳...Alerted at 2954...PALO ALTO, Calif., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it has entered into a binding term sheet for a proposed merger with Oqory, Inc., a privately-held, clinical-stage company developing ADCs for the treatment of multiple oncology indications.
Upon completion of the proposed merger, Oqory, Inc. will merge with Vincerx Pharma, Inc. Post-closing, Oqory equity holders are expected to own approximately 95% of the combined entity, while Vincerx equity holders will hold about 5%. The transaction includes a minimum fully diluted equity value of $13.66 million for existing Vincerx stockholders at closing and, as a condition to the closing of the merger, completion of a concurrent offering of Vincerx equity securities of at least $20 million. Additionally, Oqory-designated investors will provide interim financing to Vincerx of $1.5 million in two tranches, approximately $1,000,000 of which was funded today through the issuance of common stock and pre-funded warrants along with accompanying common stock warrants and approximately $500,000 of which will be funded on or prior to January 31, 2025. The merger is subject to customary closing conditions, including due diligence, regulatory approvals, negotiation of a definitive merger agreement, stockholder approval from both parties, completion of the minimum $20 million financing, and the continued listing of Vincerx's common stock on Nasdaq.
georgie18
Member Level
Re: georgie18 post# 386297
Monday, December 09, 2024 4:01:30 PM
Post#
386750
of 387642
VINC...2194...added here today...🥳
georgie18
Member Level
Re: None
Monday, December 02, 2024 9:42:03 AM
Post#
28
of 28
VINC...2954...🥳...Trying to Reverse here to the Upside...
Value_Investor
1月前
Liquidate the Pos Scam ASAP! Because there are A Series Of Bad News about the company! Here are the seventh, eighth, and nineth Bad news for VINC:
"SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates VINC, MHLD, NEUE on Behalf of Shareholders" --- see the link below for the details.
https://www.otcmarkets.com/stock/VINC/news/story?e&id=3095233
"Kuehn Law Encourages VINC, NEUE, GETY, and CLBR Investors to Contact Law Firm" --- see the link below for the details.
https://www.otcmarkets.com/stock/VINC/news/story?e&id=3098961
"Up to 1:20 Big R/S" --- see the link below for the details.
https://www.otcmarkets.com/filing/html?id=18036191&guid=Qs0-kKDmXUvnJth
"16,356,210 shares of Huge New FREE dilutions" --- see the link below for the details.
https://www.otcmarkets.com/filing/html?id=18074105&guid=Qs0-kKDmXUvnJth
So, we should see A Series Of New 52-Week-Lows until VINC hits the Final Bottom $0.025...
Are you kidding? "The next Misrosoft|? No way! The best situation is to avoid to file the BANKRUPTCY! I wish "No Bankruptcy" here so that we could see a "Dead-Cat Bounce" sometime this year!
Value_Investor
1月前
Liquidate the Pos Scam ASAP! Because there are A Series Of Bad News about the company! Here are the fourth, fifth, and sixth Bad news for VINC:
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates JWN, VINC, OMIC on Behalf of Shareholders" --- see the link below for the details.
https://www.otcmarkets.com/stock/VINC/news/story?e&id=3089437
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VINC, NEUE, ZUO on Behalf of Shareholders" --- see the link below for the details.
https://www.otcmarkets.com/stock/VINC/news/story?e&id=3092088
"VINCERX PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vincerx Pharma, Inc. - VINC" --- see the link below for the details.
https://www.otcmarkets.com/stock/VINC/news/story?e&id=3093920
Value_Investor
1月前
Liquidate the Pos Scam ASAP! Because there are A Series Of Bad News about the company! Here are the first, second, and third Bad news for VINC:
"Shareholder Alert: Ademi LLP Investigates Whether Vincerx Pharma, Inc. Is Obtaining a Fair Price for Its Public Shareholders" --- see the link below for the details.
https://www.otcmarkets.com/stock/VINC/news/story?e&id=3087853
"VINC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Vincerx Pharma, Inc. Is Fair to Shareholders" --- see the link below for the details.
https://www.otcmarkets.com/stock/VINC/news/story?e&id=3087906
"STOCKHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger - VINC, VCSA, MRNS, MHLD" --- see the link below for the details.
https://www.otcmarkets.com/stock/VINC/news/story?e&id=3089161
georgie18
2月前
VINC...40s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 29
Friday, December 27, 2024 4:19:41 PM
Post#
30
of 30
VINC....1946...🥳...Alerted at 2954...PALO ALTO, Calif., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it has entered into a binding term sheet for a proposed merger with Oqory, Inc., a privately-held, clinical-stage company developing ADCs for the treatment of multiple oncology indications.
Upon completion of the proposed merger, Oqory, Inc. will merge with Vincerx Pharma, Inc. Post-closing, Oqory equity holders are expected to own approximately 95% of the combined entity, while Vincerx equity holders will hold about 5%. The transaction includes a minimum fully diluted equity value of $13.66 million for existing Vincerx stockholders at closing and, as a condition to the closing of the merger, completion of a concurrent offering of Vincerx equity securities of at least $20 million. Additionally, Oqory-designated investors will provide interim financing to Vincerx of $1.5 million in two tranches, approximately $1,000,000 of which was funded today through the issuance of common stock and pre-funded warrants along with accompanying common stock warrants and approximately $500,000 of which will be funded on or prior to January 31, 2025. The merger is subject to customary closing conditions, including due diligence, regulatory approvals, negotiation of a definitive merger agreement, stockholder approval from both parties, completion of the minimum $20 million financing, and the continued listing of Vincerx's common stock on Nasdaq.
georgie18
Member Level
Re: georgie18 post# 386297
Monday, December 09, 2024 4:01:30 PM
Post#
386750
of 387642
VINC...2194...added here today...🥳
georgie18
Member Level
Re: None
Monday, December 02, 2024 9:42:03 AM
Post#
28
of 28
VINC...2954...🥳...Trying to Reverse here to the Upside...
georgie18
2月前
VINC....1946...🥳...Alerted at 2954...PALO ALTO, Calif., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that it has entered into a binding term sheet for a proposed merger with Oqory, Inc., a privately-held, clinical-stage company developing ADCs for the treatment of multiple oncology indications.
Upon completion of the proposed merger, Oqory, Inc. will merge with Vincerx Pharma, Inc. Post-closing, Oqory equity holders are expected to own approximately 95% of the combined entity, while Vincerx equity holders will hold about 5%. The transaction includes a minimum fully diluted equity value of $13.66 million for existing Vincerx stockholders at closing and, as a condition to the closing of the merger, completion of a concurrent offering of Vincerx equity securities of at least $20 million. Additionally, Oqory-designated investors will provide interim financing to Vincerx of $1.5 million in two tranches, approximately $1,000,000 of which was funded today through the issuance of common stock and pre-funded warrants along with accompanying common stock warrants and approximately $500,000 of which will be funded on or prior to January 31, 2025. The merger is subject to customary closing conditions, including due diligence, regulatory approvals, negotiation of a definitive merger agreement, stockholder approval from both parties, completion of the minimum $20 million financing, and the continued listing of Vincerx's common stock on Nasdaq.
georgie18
Member Level
Re: georgie18 post# 386297
Monday, December 09, 2024 4:01:30 PM
Post#
386750
of 387642
VINC...2194...added here today...🥳
georgie18
Member Level
Re: None
Monday, December 02, 2024 9:42:03 AM
Post#
28
of 28
VINC...2954...🥳...Trying to Reverse here to the Upside...
tw0122
4月前
VINC .84 + 20% …05:05 PM EDT, 10/07/2024 (MT Newswires) -- Vincerx Pharma (VINC) said its VIP943 leukemia drug showed "promising safety and tolerability," achieving two complete responses to date in a phase 1 dose-escalation study
The VIP943 antibody-drug conjugate is being evaluated in relapsed/refractory acute myeloid leukemia, higher-risk myelodysplastic syndrome and B-cell acute lymphoblastic leukemia, the company said Monday in a statement.
Another data update is expected by the end of the year, the company said.
In an update on VIP236 being evaluated in a first-in-human, phase 1 dose-escalation study as a monotherapy in patients with advanced solid tumors, the company said it intends to pursue a strategic partner to "champion its future development" in order to focus on VIP943.
Vincerx expects a cash runway into early 2025.
Shares of the company jumped 15% in after-hours activity.
Price: 0.8000, Change: +0.10, Percent Change: +
Hot Features
プレミアム
登録してリアルタイムのチャート、分析ツール、価格を入手してください。
Monksdream
2日前
glenn1919
3週前
SmokeSignals
2月前
